Bevacizumab, a monoclonal antibody against ... dose modifications of irinotecan and fluorouracil (according to the package insert) 10 were permitted in patients with treatment-related adverse ...

or were not candidates for bevacizumab treatment according to criteria outlined in the package insert and on the basis of general exclusion criteria. 17 Patients were required to discontinue from the ...